Jacobs Levy Equity Management’s Maravai LifeSciences MRVI Stock Holding History

Jacobs Levy Equity Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.42M	Buy	1,028,379 +569,478	+124%	+$2.46M	0.02%	397
2026 Q1	$1.3M	Buy	458,901 +297,809	+185%	+$1.01M	0.01%	663
2025 Q4	$524K	Sell	161,092 -37,807	-19%	-$127K	﹤0.01%	791
2025 Q3	$571K	Sell	198,899 -8,840	-4%	-$22.6K	﹤0.01%	799
2025 Q2	$501K	Sell	207,739 -285,843	-58%	-$601K	﹤0.01%	883
2025 Q1	$1.09M	Buy	493,582 +401,673	+437%	+$1.59M	﹤0.01%	793
2024 Q4	$501K	Buy	+91,909	New	+$591K	﹤0.01%	816
2024 Q2	–	Sell	-57,076	Closed	-$495K	–	1014
2024 Q1	$495K	Sell	57,076 -114,736	-67%	-$776K	﹤0.01%	817
2023 Q4	$1.13M	Buy	+171,812	New	+$1.11M	0.01%	697

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Jacobs Levy Equity Management's MRVI Position: Q2 2026 in Review

Jacobs Levy Equity Management increased its Maravai LifeSciences (MRVI) stake by 124% in Q2 2026, buying an estimated $2.46M and bringing the position to 1,028,379 shares worth $6.42M. The position accounts for 0.02% of the portfolio, ranked #397.

Jacobs Levy Equity Management first reported a position in MRVI in Q4 2023 and has held it in 9 quarters since. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Jacobs Levy Equity Management held 1,028,379 shares of Maravai LifeSciences worth $6.42M as of Q2 2026.
Jacobs Levy Equity Management bought 569,478 Maravai LifeSciences shares in Q2 2026, an estimated $2.46M.
Maravai LifeSciences made up 0.02% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #397 holding.
Jacobs Levy Equity Management first reported a position in Maravai LifeSciences in Q4 2023 and has held it in 9 quarters since.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.